We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Par, Concordia Agree to Settle FTC Charges for Sale of Generic Kapvay
Par, Concordia Agree to Settle FTC Charges for Sale of Generic Kapvay
The Federal Trade Commission has reached a settlement with Par Pharmaceuticals and Concordia Pharmaceuticals that, if finalized, would prohibit them from restraining trade in the sale of generic Kapvay, an attention deficit hyperactivity disorder drug.